FR22C1023I1 - Forme polymorphe st-246 et procedes de preparation - Google Patents

Forme polymorphe st-246 et procedes de preparation

Info

Publication number
FR22C1023I1
FR22C1023I1 FR22C1023C FR22C1023C FR22C1023I1 FR 22C1023 I1 FR22C1023 I1 FR 22C1023I1 FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 I1 FR22C1023 I1 FR 22C1023I1
Authority
FR
France
Prior art keywords
preparation
methods
polymorphic form
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1023C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of FR22C1023I1 publication Critical patent/FR22C1023I1/fr
Application granted granted Critical
Publication of FR22C1023I2 publication Critical patent/FR22C1023I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/724,7-Endo-alkylene-iso-indoles
    • C07D209/764,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
FR22C1023C 2010-03-23 2022-06-02 Forme polymorphe st-246 et procedes de preparation Active FR22C1023I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31674710P 2010-03-23 2010-03-23
US37303110P 2010-08-12 2010-08-12
PCT/US2011/029576 WO2011119698A1 (fr) 2010-03-23 2011-03-23 Formes polymorphes st-246 et procédés de préparation

Publications (2)

Publication Number Publication Date
FR22C1023I1 true FR22C1023I1 (fr) 2022-07-22
FR22C1023I2 FR22C1023I2 (fr) 2024-02-16

Family

ID=44656766

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1023C Active FR22C1023I2 (fr) 2010-03-23 2022-06-02 Forme polymorphe st-246 et procedes de preparation

Country Status (20)

Country Link
US (6) US9339466B2 (fr)
EP (1) EP2549871B1 (fr)
JP (3) JP6018041B2 (fr)
KR (6) KR20160028489A (fr)
CN (4) CN105175311A (fr)
AP (1) AP3221A (fr)
AU (1) AU2011232551B2 (fr)
BR (1) BR112012023743B1 (fr)
CA (2) CA3030671A1 (fr)
CL (1) CL2012002621A1 (fr)
DK (1) DK2549871T3 (fr)
FR (1) FR22C1023I2 (fr)
IL (4) IL221991B (fr)
MX (1) MX361428B (fr)
NZ (1) NZ602578A (fr)
PE (2) PE20170944A1 (fr)
RU (2) RU2015146899A (fr)
SG (2) SG184201A1 (fr)
WO (1) WO2011119698A1 (fr)
ZA (1) ZA201207141B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US9339466B2 (en) * 2010-03-23 2016-05-17 Siga Technologies, Inc. Polymorphic forms of ST-246 and methods of preparation
EP3656763A1 (fr) 2012-08-16 2020-05-27 Siga Technologies, Inc. Procédés de préparation de técovirimat
AU2014290333B2 (en) 2013-07-19 2018-11-08 Siga Technologies, Inc. Amorphous Tecovirimat preparation
JP6594303B2 (ja) * 2013-11-19 2019-10-23 シガ・テクノロジーズ・インコーポレーテッド 微粒子化テコビリマット一水和物の再水和
EP3197435A1 (fr) * 2014-09-26 2017-08-02 Millendo Therapeutics, Inc. Forme médicamenteuse solide du chlorhydrate de n-(2,6-bis(1-méthyléthyl)phényl)-n'-((1-(4-(diméthylamino) phényl)cyclopentyl)méthyl)urée et compositions, procédés et kits s'y rapportant
JP7074677B2 (ja) 2016-02-16 2022-05-24 シガ・テクノロジーズ・インコーポレーテッド St-246(テコビリマット一水和物)懸濁製剤
US11677080B2 (en) 2017-03-31 2023-06-13 Osaka Gas Co., Ltd. Electrochemical element, electrochemical module, solid oxide fuel cell and manufacturing method
RU2716709C1 (ru) * 2019-08-20 2020-03-16 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Пероральная лекарственная форма препарата в капсулах для лечения и профилактики заболеваний, вызываемых ортопоксвирусами
WO2023080188A1 (fr) * 2021-11-04 2023-05-11 興和株式会社 Capsule
TW202320728A (zh) * 2021-11-04 2023-06-01 日商興和股份有限公司 醫藥品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670901A1 (de) * 1967-08-09 1971-03-18 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US4173646A (en) * 1974-10-04 1979-11-06 Merck & Co., Inc. Tricyclicdicarboximides
US4061763A (en) * 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
US5068356A (en) * 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
CA2396079A1 (fr) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
AU2256702A (en) 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
ES2632313T3 (es) 2003-06-20 2017-09-12 Siga Technologies Inc. Compuestos, composiciones y métodos para el tratamiento y la prevención de infecciones por ortopoxvirus y enfermedades asociadas
JPWO2005065715A1 (ja) 2003-12-25 2007-07-26 武田薬品工業株式会社 造粒性改善方法
DK1838670T3 (da) * 2004-12-09 2010-03-01 Zach System Spa Fremgangsmåde til fremstilling af carvedilol og dets enantiomere
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
ES2395101T3 (es) 2006-03-02 2013-02-08 Siga Technologies, Inc. Medicamentos antivirales para tratamiento de infecciones por arenavirus
CN104758281A (zh) 2007-04-23 2015-07-08 西佳技术公司 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
CN101445478B (zh) * 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 含一个结晶水的化合物st-246及其晶体与制备方法
RU2412160C1 (ru) * 2009-09-25 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) 7-[n'-(4-трифторметилбензоил)-гидразинокарбонил]-трицикло[3.2.2.02,4]нон-8-ен-6-карбоновая кислота, обладающая противовирусной активностью
US9339466B2 (en) * 2010-03-23 2016-05-17 Siga Technologies, Inc. Polymorphic forms of ST-246 and methods of preparation

Also Published As

Publication number Publication date
KR20170102070A (ko) 2017-09-06
KR20150011016A (ko) 2015-01-29
SG184201A1 (en) 2012-10-30
US10933050B2 (en) 2021-03-02
CA2793533A1 (fr) 2011-09-29
CA3030671A1 (fr) 2011-09-29
IL258239A (en) 2018-05-31
JP2013522371A (ja) 2013-06-13
KR20160028489A (ko) 2016-03-11
US20180311213A1 (en) 2018-11-01
KR20150092354A (ko) 2015-08-12
EP2549871A4 (fr) 2016-03-09
BR112012023743B1 (pt) 2020-02-18
AP3221A (en) 2015-04-30
RU2012144818A (ru) 2014-04-27
NZ602578A (en) 2014-08-29
US9744154B2 (en) 2017-08-29
CN103068232A (zh) 2013-04-24
KR20130018271A (ko) 2013-02-20
US20180193308A1 (en) 2018-07-12
CN105111131A (zh) 2015-12-02
AU2011232551B2 (en) 2014-11-13
IL241731A0 (en) 2015-11-30
MX2012010859A (es) 2013-04-29
US10045964B2 (en) 2018-08-14
FR22C1023I2 (fr) 2024-02-16
IL241730A0 (en) 2015-11-30
SG10201501936PA (en) 2015-05-28
RU2578606C2 (ru) 2016-03-27
PE20130212A1 (es) 2013-03-09
JP6018041B2 (ja) 2016-11-02
BR112012023743A2 (pt) 2015-09-15
IL221991B (en) 2019-06-30
WO2011119698A1 (fr) 2011-09-29
US20210137885A1 (en) 2021-05-13
ZA201207141B (en) 2016-06-29
US20160107993A1 (en) 2016-04-21
WO2011119698A9 (fr) 2013-01-31
CN105111130A (zh) 2015-12-02
CL2012002621A1 (es) 2013-10-11
RU2015146899A (ru) 2019-01-11
CN103068232B (zh) 2015-08-26
US20190343799A1 (en) 2019-11-14
US20110236434A1 (en) 2011-09-29
MX361428B (es) 2018-12-06
AP2012006514A0 (en) 2012-10-31
PE20170944A1 (es) 2017-07-13
JP2016040323A (ja) 2016-03-24
CA2793533C (fr) 2019-02-26
DK2549871T3 (en) 2018-12-10
AU2011232551A1 (en) 2012-10-18
EP2549871B1 (fr) 2018-08-22
CN105175311A (zh) 2015-12-23
US11890270B2 (en) 2024-02-06
KR20160062208A (ko) 2016-06-01
US9339466B2 (en) 2016-05-17
JP2018012735A (ja) 2018-01-25
US10406137B2 (en) 2019-09-10
EP2549871A1 (fr) 2013-01-30

Similar Documents

Publication Publication Date Title
FR22C1023I1 (fr) Forme polymorphe st-246 et procedes de preparation
IL226477A (en) Salts and polymorphic forms of Aptinib
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ES2966088T3 (es) Nuevos métodos de evolución de proteínas
ZA201303813B (en) Methods of treatment using lipid compounds
IT1400092B1 (it) Metodo di crioconservazione di polpa dentale
BR112013014435A2 (pt) membro de hppe e método de preparação de um membro de hppe
CO6990730A2 (es) Composición microbicida y proceso de obtención de la misma
IT1402029B1 (it) Procedimento per la preparazione di erlotinib
ITBS20100012A1 (it) Procedimento per la preparazione di fluazinam
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos
EP2588428A4 (fr) Méthodes d'analyse de kinome
BR112013014291A2 (pt) formulação lipossômica de calcetrapib
IT1400937B1 (it) Procedimento per ottenere propoli anallergica
FR2955473B1 (fr) Structure de presentoir
BR112012029669A2 (pt) composição e método
FR2956419B1 (fr) Elements de construction calorifuges
FR2999175B1 (fr) Procede d'isolement de diamandoides
BR112013013441A2 (pt) composição de adesivo-engomadura e métodos relacionados
FI20105265A0 (fi) Jäähdytin ja valmistusmenetelmä
EP2647632A4 (fr) Procédé de préparation d'un mésylate de a-imatinib
DE112011102778A5 (de) Magnetovariationales Verfahren
FI20100388A0 (fi) Viljelymenetelmä